SCHEMBL4677066

SCHEMBL4677066

O=C(Cc1cc(Cc2ccccc2F)cs1)C(=O)c1nc[nH]n1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPN1 P18031 1/20 0.35
ELOVL1 Q9BW60 2/20 0.34
HDAC6 Q9UBN7 1/20 0.34
MEN1 O00255 5/20 0.33
KMT2A Q03164 5/20 0.33
RAB9A P51151 4/20 0.33
ABL1 P00519 1/20 0.33
HPGD P15428 2/20 0.32
PRKACA P17612 1/20 0.32
ROCK1 Q13464 1/20 0.32
LMNA P02545 1/20 0.32
NPC1 O15118 2/20 0.32
HTT P42858 2/20 0.32
MAPT P10636 1/20 0.32
MAPK1 P28482 1/20 0.32
TAAR1 Q96RJ0 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
SNCA P37840 1/20 0.32
KDM4E B2RXH2 1/20 0.31
AR P10275 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4674195 0.92 ABL1 (0.35) PTPN1ELOVL1HDAC6MEN1KMT2A
SCHEMBL4671873 0.86 LTB4R (0.39) HDAC6LMNAMAPK1
SCHEMBL4673251 0.84 LMNA (0.34) HDAC6MEN1KMT2ARAB9AABL1
SCHEMBL4676763 0.83 HCAR2 (0.38) MEN1KMT2ARAB9APRKACAROCK1
SCHEMBL4673451 0.83 PTPN1 (0.35) PTPN1ELOVL1HDAC6MEN1KMT2A
SCHEMBL4670936 0.83 ABL1 (0.38) ELOVL1MEN1KMT2ARAB9AABL1
SCHEMBL4675134 0.82 POLB (0.34) MEN1KMT2ARAB9AHPGDLMNA
SCHEMBL4670908 0.81 PTPN1 (0.35) PTPN1HDAC6MEN1KMT2ATAAR1
SCHEMBL4676076 0.81 AR (0.33) ELOVL1MEN1KMT2ARAB9AABL1
SCHEMBL4677411 0.81 POLB (0.32) HDAC6MEN1KMT2ARAB9AHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1142872-B1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO (JP) 2008-10-15 EP disclosed
US-7098201-B2 Heteroaromatic derivatives having an inhibitory activity against HIV integrase SHIONOGI & CO., LTD. (JP) 2006-08-29 US disclosed
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase FUJISHITA TOSHIO (JP) 2004-01-01 US disclosed
US-6645956-B1 1-(5-(4-fluorobenzyl)furan-2-yl)-3-hydroxy-3-(1H-1,2,4-triazol-3 -yl)-propenone; viricides; AIDS treatment SHIONOGI & CO., LTD. (JP) 2003-11-11 US disclosed
US-6620841-B1 Furan or benzofuran derivatives substituted with triazole; acquired immunodeficiency syndrome (AIDS) SHIONOGI & CO., LTD. (JP) 2003-09-16 US disclosed
EP-1142872-A1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO., LTD. (JP) 2001-10-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase RCOR1, BCOR, CYP8B1 PTPN1 2715/4885ELOVL1 4468/4885HDAC6 1000/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.